Cediranib

From Dog
Revision as of 23:07, 5 April 2013 by WikiSysop (talk | contribs) (Created page with "Cediranib ( (4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline)) is a protein kinase inhibitor chemotherapy agent used in can...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Cediranib ( (4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline)) is a protein kinase inhibitor chemotherapy agent used in canine medicine against a number of neoplasm.

Cediranib is a potent inhibitor of vascular endothelial growth factor but cannot cross the blood-brain barrier[1]. It is metabolized by the liver[2].

Recommended dose rate in dogs is 0.5 - 1.0 mg/kg daily per os.

References

  1. Wang T et al (2012) Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J Pharmacol Exp Ther 341(2):386-395
  2. Schulz-Utermoehl T et al (2010) In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos 38(10):1688-1697